

# A multipronged attack on Latent, Active and Resistant strains of Mycobacterium tuberculosis

### Abstract

The bacterium *Mycobacterium tuberculosis*, also referred to as *MTb*, infects individuals in latent, active and resistant forms. There are recommended regimens for the delivery of established antibiotics to infected individuals. These regimens focus on the oral administration and involve relatively large doses that often result in significant side effects. This invention is a biodegradable implant composed primarily of an inert saturated fatty acid, namely stearic acid. The antibiotic is incorporated into the stearic acid matrix along with other constituents. The composition also includes a salt to regulate the release rate of the antibiotic, a metal-stearate structure to provide additional toxicity against *MTb*, ascorbic acid, and unsaturated fatty acids in low concentrations. As the fatty acid implant dissolves it forms a micelle that encapsulates the antibiotic. The micelle is transported to the infected area by serum and, since it is a primary energy source for the bacterium, is consumed. The antibiotic is hidden in the matrix (micelle). The biodegradable implant, which can be inserted as a single component or a as spheres of different sizes (i.e. micrometer) does not have to be removed.

## Background

#### **Tuberculosis**

- Causative agent is Mycobacterium tuberculosis
- Strikes in the lungs and slowly dissolves the tissues
- Diagnosed via Sputum Test, Tuberculin Skin Test, or TB Blood Test
- Easily spread by airborne transmission through coughing or sneezing



Figure 1. Computer generated image of drug-resistant *Mycobacterium* tuberculosis



Figure 2. Annual tuberculosis incidence(per 100,000), by regionworldwide in 2017

Strain	Drug	Side Effe
Active	<ul> <li>Isoniazid</li> <li>Rifampin</li> <li>Pyrazinamide</li> <li>Ethambutol</li> <li>Streptomycin</li> </ul>	<ul> <li>Hepatitis</li> <li>Jaundice</li> <li>Dizziness and I balance</li> <li>Nausea and vo</li> <li>Seizure</li> </ul>
Latent	<ul> <li>Rifampin</li> <li>Isoniazid</li> <li>Isoniazid and Rifapentine</li> </ul>	<ul> <li>Hallucinations</li> </ul>
Resistant	<ul><li>Capreomycin</li><li>Fluoroquinolones</li></ul>	<ul><li>Nephrotoxicity</li><li>Renal Damage</li></ul>

Courtney Johnson, Torien Beard, Thomas Manning (faculty advisor) Department of Chemistry, Valdosta State University

# ects

loss of miting



# Implant

Existing Drugs	Our In
<ul> <li>Expensive</li> <li>Oral administration</li> <li>Large dosages</li> <li>Must be removed</li> </ul>	<ul> <li>Cost e</li> <li>Biodeg</li> <li>Lower</li> <li>Does not have</li> </ul>
Leucine, Valine, Isoleuine Essential AA for MTb m Low concentration (< 5% Sodium Chloride, strong electrolyte, impacts rate of release (<30%) Leu, Val, Iso NaCl Cholesterol	Copper Stearate- Stearate building block of cell wall, Toxic to MTb (<2%) Cu Stearate VC
Saturated Fatty Oleic	Stearic Acid



### Figure 3. Composition of the implant

acid, MTb toxicity

(<2%)

Composition	Signi
Amino Acids	Essential nutrients for
Cholesterol	Survival of MTb is ba accumulation of chol
Copper Complexes	Used to increase war unwanted hydrogen structural rigidity and detection in the immu
Vitamin C	Used to protect the in reaction that can nat serum
Stearic Acid	Mimics the cell memory of <i>Mycobacterium tu</i>
PEG 3350	Used for solubility, ag release rate
Sodium Acetate	Encourages dissoluti
Oleic Acid	Low toxicity decrease
Sodium Chloride	Strong electrolyte im

Name of acid	Type of Fatty Acid	# of Carbons	Melting point (°C)	Water Solubility (mg/L)	Electrolyte Name	Type Electrolyte	Function
Oleic Acid	Unsaturated	18	13.4	Insoluble	Sodium Chloride (NaCl)	Strong	<ul> <li>Regulates drug release rate</li> </ul>
Stearic Acid	Acid Saturated 18 69.3 0.597		0.597	Sodium Acetate (NaAc)	Strong	<ul> <li>Increase water solubility and faster release rate</li> </ul>	
tion of the original of the or			Calcium Carbonate (CaCO <sub>3</sub> )	Weak	<ul> <li>Dissolves at slower rate</li> <li>Longer drug release rate</li> <li>Negative effects</li> </ul>		

Figure 5. Stearic acid is used as a matrix to contain a dozen molecular species used to attack/weak Mycobacterium tuberculosis. Tablets and dust of different sizes and shapes have been used to date. A tablet containing the medicinal species will be emerged in water for almost a month, and then molecular species will slowly leach out into the aqueous phase. This replicates what would take place in in vivo.

## nplant

effective gradable dosage e to be removed



#### ificance

- or MTb survival. ased on the lesterol ater solubility, block
- bonding, increase help to escape une system
- mplant from redox turally occur in human
- brane uberculosis ggregate formation and
- ion rate e the survival rate pacts rate of release



![](_page_0_Figure_41.jpeg)

Figure 4. Conductivity comparison of Stearic Acid (left) vs Stearic Acid and Sodium Acetate (right). Hundreds of measurements were made by our group, this is representative data.

# **Mechanism of Action** Bacterial targeting tiss Lipase VAN release Live bacteria

![](_page_0_Picture_44.jpeg)

### References

MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets — 2017. MMWR Morb Mortal Wkly Rep 2019;68:263–266.

For more information contact: Dr. Thomas Manning (Tmanning@Valdosta.edu)

![](_page_0_Picture_48.jpeg)